Our business is your health
At Regeneron we make it our business every day to bring innovative thinking to the challenge of discovering and developing new medicines. Our pursuit has one singular intent – to improve therapeutic outcomes for patients.
Our first approved product, ARCALYST® (rilonacept), an anti-inflammatory agent, has been available to patients in the U.S. since 2008. In late 2011, we launched EYLEA® (aflibercept) Injection, also known in the scientific literature as VEGF Trap-Eye and Intravitreal Aflibercept Injection. We received approval from the FDA for a second indication in September 2012 and approval for a third indication in October 2014. In August 2012, Regeneron and Sanofi, obtained FDA approval for ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion.
We are a leader in human antibody technologies and have built a pipeline of antibody drug candidates against both novel and validated drug targets in diseases ranging from cancer to rheumatoid arthritis and hypercholesterolemia.
Our strategic antibody collaboration with Sanofi provides committed long-term funding and expertise to supplement our own. Our business is creating and commercializing new medicines for patients – at Regeneron our business is your health.